Aromatase inhibitors are increasingly used in the treatment of early and metastatic breast cancer. They can produce various skin adverse effects but are only rarely associated with cutaneous vasculitis. We report the first case of cutaneous vasculitis clearly associated with the use of aromatase inhibitor letrozole.
XuH-BLiuY-JLiL. Aromatase inhibitor versus tamoxifen in postmenopausal woman with advanced breast cancer: a literature-based meta-analysis. Clin Breast Cancer2011; 4: 246–251.
2.
JhaveriKHalperinPShinSJ. Erythema nodosum secondary to aromatase inhibitor use in breast cancer patients: case reports and review of the literature. Breast Cancer Res Treat2007; 106: 315–318.
ChenKRCarlsonJA. Clinical approach to cutaneous vasculitis. Am J Clin Dermatol2008; 9: 71–92.
7.
ShodaHInokumaSYajimaN. Cutaneous vasculitis developed in a patient with breast cancer undergoing aromatase inhibitor treatment. Ann Rheum Dis2005; 64: 651–652.
8.
WongMGrossmanJHahnBH. Cutaneous vasculitis in breast cancer treated with chemotherapy. Clin Immunol2008; 129: 3–9.
9.
van VollenhovenRF. Adhesion molecules, sex steroids, and the pathogenesis of vasculitis syndromes. Curr Opin Rheumatol1995; 7: 4–10.
